8-K filed May 5, 2025, 7:59 PM ET CIK 0001463361

other material confidence high sentiment negative materiality 1.00

Unity Biotechnology, Inc.: restructuring charge — Unity Biotech lays off all employees, explores strategic alternatives after Phase 2b miss

Unity Biotechnology, Inc.

Company reducing entire workforce; expects $3.7M in severance and related cash costs; completion by May 15, 2025.
CEO Anirvan Ghosh, CFO Lynne Sullivan, and Chief Legal Officer Alexander Nguyen will terminate employment May 15, transition to advisory consulting roles.
Phase 2b ASPIRE study of UBX1325 in DME showed non-inferiority to aflibercept at week 36 but missed primary endpoint at average of weeks 20 and 24.
Strategic alternatives include sale, license, monetization, merger, or wind-down of the company; no assurance of any transaction.
Cash and equivalents $16.9M as of March 31, 2025; company reducing operational cash burn.

item 2.05 item 8.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anirvan Ghosh

Chief Executive Officer

Unity Biotechnology, Inc.

Effective: 2025-05-15
Filed: May 5, 2025, 7:59 PM ET

each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025

Departed

Lynne Sullivan

Chief Financial Officer and Head of Corporate Development

Unity Biotechnology, Inc.

Effective: 2025-05-15
Filed: May 5, 2025, 7:59 PM ET

each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025

Departed

Alexander Nguyen

Chief Legal Officer and Head of Operations

Unity Biotechnology, Inc.

Effective: 2025-05-15
Filed: May 5, 2025, 7:59 PM ET

each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anirvan Ghosh departed as Chief Executive Officer at Unity Biotechnology, Inc..

Action: terminated employment
Role: Chief Executive Officer

Exact text from the filing

each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lynne Sullivan departed as Chief Financial Officer and Head of Corporate Development at Unity Biotechnology, Inc..

Action: terminated employment
Role: Chief Financial Officer and Head of Corporate Development

Exact text from the filing

each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander Nguyen departed as Chief Legal Officer and Head of Operations at Unity Biotechnology, Inc..

Action: terminated employment
Role: Chief Legal Officer and Head of Operations

Exact text from the filing

each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Unity Biotechnology, Inc. announced a restructuring with charges of approximately $3.7 million (a reduction in force affecting all of its employees).

Type: restructuring
Charge: approximately $3.7 million
Headcount: a reduction in force affecting all of its employees

Exact text from the filing

The Company estimates that it will incur aggregate cash expenses of approximately $3.7 million in connection with the reduction in force, including severance, benefits, and related termination costs, which includes fees to be paid under consulting agreements.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Source: SEC EDGAR

accession 0000950170-25-063167

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.